Objectives: To identify pre-treatment factors affecting the duration of post-surgical steroid replacement in patients undergoing adrenalectomy for subclinical Cushing syndrome. Methods: The present retrospective analysis included 64 patients who underwent unilateral laparoscopic adrenalectomy for subclinical Cushing syndrome. Adrenal tumor and contralateral adrenal sizes together with various clinical factors were studied in association with the duration of post-surgical steroid replacement. Adrenal tumor and contralateral adrenal size were measured at the level of the maximum transverse plane of the adrenal glands using computed tomography scan or magnetic resonance imaging. Cox's proportional hazards model was used for the statistical analysis. Results: All 64 patients were treated with post-surgical steroid replacement after adrenalectomy. The median duration of the steroid treatment was 6 months. When assessing the duration of post-surgical steroid replacement, contralateral adrenal volume <0.745 cm 3 , contralateral adrenal width <6.15 mm and serum cortisol after a 1-mg dexamethasone suppression test >2.65 lg/dL were significant predictors of prolonged post-surgical steroid treatment on univariate analysis. On multivariate analysis, contralateral adrenal width <6.15 mm was the only independent predictive factor for the prolonged post-surgical steroid replacement. Conclusions: Contralateral adrenal width seems to represent a significant predictive factor for the duration of post-surgical steroid replacement in subclinical Cushing syndrome patients. Pre-surgical assessment of image findings might help clinicians determine the total duration of steroid therapy after adrenalectomy.
Introduction
SCS is a defined condition of cortisol excess in patients with adrenal adenoma without the typical clinical signs and symptoms of CS. In 1981, Charbonnel et al. reported a patient with no clinical features of CS as pre-CS. 2 As SCS is asymptomatic, it is often found as adrenal incidentaloma. Recently, improvements in abdominal imaging techniques have increased the detection of adrenal incidentalomas. 3, 4 SCS is reported in 2.9-20% of patients with incidentally discovered adrenal masses. [5] [6] [7] [8] Laparoscopic adrenalectomy has become a standard approach for adrenal tumors, even for SCS patients. Laparoscopic adrenalectomy is safe, feasible and beneficial with the improvement of hypertension, bodyweight and glucose tolerance. 9, 10 In SCS patients, the HPA axis has been suppressed by the activity of the tumor, thereby the contralateral adrenal cortex has undergone atrophic change at the time of diagnosis. Although suppression of endogenous cortisol production varies among patients, postoperative steroid replacement is recommended, as adrenal insufficiency can be critical. 3, 8, 11 In contrast, it is difficult to predict the total duration of postoperative steroid replacement before surgery. A precautionary steroid treatment has been proposed for all SCS patients after unilateral adrenalectomy. Even recent reviews have failed to reach univocal and definitive conclusions regarding the duration of steroid replacement for SCS patients due to the heterogeneity of the tumor activity and the etiology of hypercortisolism. 8, 12 Therefore, to estimate the total duration of post-surgical steroid replacement is challenging.
To date, few studies have focused on the clinical factors leading to prolonged steroid replacement after surgery. The aim of the present study was to assess and identify the preoperative clinical variables, including imaging data, that can predict the duration of post-surgical steroid replacement in patients after laparoscopic adrenalectomy for SCS.
Methods

Study cohort
The clinical variables associated with the duration of steroid replacement after adrenalectomy for SCS were examined retrospectively among 68 patients who underwent retroperitoneal laparoscopic adrenalectomy for SCS between March 2005 and May 2016 at Chiba University Hospital, Chiba, Japan. Four patients were excluded from the present study because of a bilateral adrenal tumor, ACTH independent macronodular hyperplasia or missing values. Finally, 64 patients were included in this study. Surgery was carried out by several dedicated surgeons. Tumors were pathologically confirmed as cortical adenoma in all patients.
Definition
We diagnosed SCS on the basis of the diagnostic criteria proposed by the American Endocrine Society and the Research Committee for Adrenal Diseases provided by the Japanese Ministry of Health, Labor and Welfare. 13, 14 These criteria include the presence of adrenal incidentaloma, the lack of Cushingoid features and normal basal serum cortisol levels without suppression by an overnight low-dose (>1.8 lg/dL with 1 mg) and a high-dose (>1 lg/dL with 8 mg) DST, and at least one of the following additional endocrine abnormalities: (i) suppressed plasma ACTH (<10 pg/mL) and/or decreased response to CRH stimulation (<150% increase compared with baseline); (ii) loss of cortisol diurnal rhythm (>5 lg/dL at midnight) and decreased serum dehydroepiandrosterone sulfate levels (less than age-and sexmatched reference values); and (iii) unilateral radioactive uptake, as determined by adrenal scintigraphy. 15 Hypertension was defined as systolic blood pressure ≥140 mmHg and/ or diastolic blood pressure ≥90 mmHg or use of antihypertensive treatment. Hyperlipidemia was defined as total cholesterol ≥200 mg/dL (5.17 mmol/L), or as the use of cholesterol-lowering drugs. Diabetes was defined as fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) on at least two samples and/or plasma glucose ≥200 mg/dL (11.1 mmol/L) 2 h after a 75-g oral glucose tolerance test, or random plasma glucose ≥200 mg/dL (11.1 mmol/L) or as the use of antidiabetic treatment. However, the diagnostic criteria of diabetes or hyperlipidemia have been changed and all cases were not diagnosed by consistent diagnostic criteria as it is a long-term retrospective study.
Data collection
The following baseline variables were collected from medical records: age, sex, BMI, clinical presentations, tumor side, operative data, clinical laboratory data and the duration of post-surgical steroid replacement. There were no missing values in these baseline variables. The laboratory data included serum cortisol level in the morning and evening, urinary cortisol levels, ACTH level in the morning and evening, cortisol level after 1-mg and 8-mg DST, the presence of aldosteroneproducing adenoma and/or osteoporosis and/or hypertension and/or hyperlipidemia and/or diabetes and/or obesity. Operative data included operative approach, operative time, blood loss and intraoperative complications. All patients underwent a CT scan or MRI. Imaging parameters were collected as follows: adrenal length, width, height, volume in tumor and contralateral adrenal side. The cross-sectional areas of the adrenal gland were measured in both the axial and coronal planes.
Adrenal maximum diameter was measured as length in the axial plane. Width was defined as the transverse diameter that crossed the adrenal maximum diameter at right angles in the axial plane. Length and width were crossed at right angles. Maximum height was measured as height in the coronal plane. Volume calculations were carried out using the formula of an ellipsoid as follows:
These measurements were made by two independent clinicians, neither of whom had any knowledge or information pertaining to the patients' clinical status.
Postoperative management
All patients underwent post-surgical steroid replacement following the institutional replacement protocol. On the operation day, patients received 50 mg hydrocortisone three times a day in total of 150 mg i.v. On the next day of surgery, patients received 30 mg hydrocortisone three times a day in total of 90 mg i.v. Two days after surgery, patients received 40 mg hydrocortisone in the morning and 20 mg in the evening in total of 60 mg orally. Three days after surgery, patients received 30 mg and 10 mg hydrocortisone each in total of 40 mg orally. Afterwards, the amount of hydrocortisone was decreased according to the patient's condition. Usually they were discharged when the amount of hydrocortisone reached 30 mg as the daily dose. In the outpatient department, an endocrine physician determined the final tapering course for the patients weaning off of steroids; all of the patients received repeat biochemical tests to confirm the recovery of the HPA axis before discontinuing steroid replacement therapy. The patients had examinations bimonthly for the first month after operation, and once a month afterwards. In terms of the clinical symptoms it was important to see whether the patients developed the signs of hypocortisolism, such as fatigue, nausea, dizziness, hypotension and so on. The dose of hydrocortisone was increased again for those patients who developed hypocortisolism while tapering the steroid. If the patient did not show symptoms of adrenal insufficiency and the cortisol level was shown to be approximately 10 lg/dL in the morning without hydrocortisone administration, and there was no abnormality in the electrolyte and plasma glucose level, steroid replacement was stopped.
Statistical analysis
The results are reported as medians (range). Cox proportional hazards modeling was used to carry out univariate and multivariate analyses. We derived relative risks and 95% confidence intervals. First, univariate analyses were used to evaluate the associations between prolonged duration of steroid replacement (>6 months) and the following preoperative variables: age, sex, tumor side, BMI, arterial hypertension, osteoporosis, hyperlipidemia, diabetes, preoperative laboratory data, imaging data and intraoperative variables. Second, the candidate variables were selected with a P-value <0.05 based on univariate analyses. Third, a multivariate analysis was carried out using preoperative data to identify variables associated with prolonged duration of post-surgical steroid replacement. Next, Pearson's r correlation was used to measure the degree of relationship between variables that were statistically significant in univariate analysis and the duration of post-surgical steroid replacement. Furthermore, the cut-off value was examined by variables that were statistically significant in multivariate analysis on the ROC curve. The value with the maximum sensitivity and minimal loss of specificity was chosen. All statistical analyses were carried out with JMP software (version 13.0; SAS Institute, Cary, NC, USA). Two-sided values of P < 0.05 were considered statistically significant.
Ethics statement
This study was approved by the institutional review board (No. 2564) of Chiba University Hospital, and written informed consent was obtained from the patients.
Results
Preoperative patient characteristics are summarized in Table 1 .
In the present study, the median age was 59 years (range 31-74 years). Among 64 patients, 36 cases were a left adrenal tumor and 28 cases were a right tumor. The median tumor length was 28.5 mm (range 11-73 mm). The median operation time was 175 min (range 100-448 min). Only one case converted to open surgery. Median duration of post-surgical steroid replacement was 6 months (range 1-50 months). Of the 64 patients, 27 required steroid replacement for >7 months. The median duration of post-surgical steroid replacement in the 27 patients was 12 months (range 7-50 months). The median duration of post-surgical steroid replacement in the 37 patients was 4 months (range 1-6 months). Clinical variables significantly associated with prolonged steroid replacement included adrenal width of contralateral side <6.15 mm (P < 0.001), adrenal volume of contralateral side <0.745 cm 3 (P = 0.0011) and serum cortisol after a 1-mg DST >2.65 lg/dL (P = 0.0402) on univariate analysis (Table 1) . On multivariate analysis, only adrenal width of the contralateral side <6.15 mm (P = 0.0027) was identified as an independent predictor of prolonged steroid replacement ( Table 2) . Table 3 shows that the adrenal width (r = À0.5473, P < 0.0001) and volume (r = À0.40618, P = 0.0009) of the contralateral side were correlated with the duration of postsurgical steroid replacement. The correlation diagrams are shown in Figure 1 .
Next, we tried to find the optimum cut-off value using the AUC derived from the ROC curve for the contralateral adrenal width for the duration of post-surgical steroid replacement in SCS patients. Contralateral adrenal width <5.8 mm was the suitable cut-off value for the duration of post-surgical steroid replacement in SCS patients (Fig. 2) .
To compare the adrenal size in SCS with a normal adrenal gland, we retrospectively examined renal cancer patients with a normal adrenal gland. There were 64 patients who underwent tumor resection between October 2016 and January 2017 at Chiba University Hospital. We examined the adrenal gland on the opposite side of the renal cancer. The median adrenal length was 13.2 mm. The median adrenal width was 7.55 mm. The median adrenal volume was 1.015 cm 3 . Generally, contralateral adrenal width in SCS patients was narrower than in patients who had normal adrenal glands.
Next, to investigate whether the contralateral adrenal width was the significant predictive factor for the duration of postsurgical steroid replacement in CS patients, we retrospectively examined 21 CS patients who underwent laparoscopic adrenalectomy between July 2008 and September 2017 at Chiba University Hospital. Preoperative patient characteristics are summarized in Table 4 .
The median duration of post-surgical steroid replacement was 14 months (range 4-47 months). No significant association was observed between preoperative imaging data and the duration of post-surgical steroid replacement. Generally, contralateral adrenal width in CS patients was narrower than in SCS patients.
Discussion
Adrenal insufficiency after unilateral adrenalectomy for cortisol-secreting adenoma is potentially fatal if not treated. Therefore, patients who undergo adrenalectomy for SCS require post-surgical glucocorticoid replacement treatment. 3, 8, 11 The total duration of steroid replacement therapy differs from reported series. The recovery of the HPA axis should be evaluated every 3-6 months and dosage should be tapered accordingly. A few studies reported that patients with normal adrenal function preoperatively do not require routine post-surgical steroid replacement after unilateral adrenalectomy. 17 However, it has been shown that some of these patients might present post-surgical hypocortisolism. 18, 19 Thus, post-surgical hypocortisolism is unpredictable by preoperative biochemical adrenal function tests in patients with adrenal adenoma. 19 A precautionary steroid treatment has been proposed for all SCS patients after unilateral adrenalectomy, regardless of preoperative adrenal functional evaluation.
Although few reports so far have focused on the duration of post-surgical steroid replacement, Raffaelli et al. stated that postoperative glucocorticoid replacement treatment is advisable in all patients with SCS and CS. 20 To date, few studies have focused on the pre-surgical imaging data leading to prolonged steroid replacement after surgery. In this present study, we provide evidence of the correlation between presurgical image findings and the duration of post-surgical steroid replacement for SCS.
SCS is asymptomatic and often found as adrenal incidentaloma, the activity of the tumor at diagnosis varies among patients. In the present study, the temporary activity of tumors, such as cortisol excess or ACTH suppression, at the diagnosis were not correlated to the duration of steroid replacement. We found that the contralateral adrenal width was correlated to the duration of steroid replacement. The atrophy of the contralateral adrenal gland is thought to depend on the duration of potential morbidity. Therefore, the duration of potential morbidity might reflect contralateral adrenal width, and as a result might affect the duration of post-surgical steroid replacement. These results suggested that prolonged duration of morbidity causes the atrophic change of the contralateral adrenal gland, and might lead to delayed recovery of the HPA axis, requiring prolonged duration of steroid replacement in SCS patients after surgery.
In this present study, we focused on only SCS patients. Some studies stated that prolonged adrenal insufficiency is more frequent in CS patients than in SCS patients. [20] [21] [22] As CS is symptomatic, the duration of potential morbidity might be shorter than SCS. In addition, the recovery of the HPA axis might depend on the activity of the tumor itself. 22, 23 Thus, SCS and CS could have different biological behavior, and must be considered separately. Indeed, no significant association was observed between preoperative imaging data and the duration of post-surgical steroid replacement in CS patients.
Clinical variables significantly associated with prolonged steroid replacement included adrenal width, volume of the contralateral side and serum cortisol after the 1-mg DST on univariate analysis. Although both adrenal width and volume of the contralateral side were correlated with the duration of post-surgical steroid replacement, only the contralateral adrenal width was identified as the independent predictor on multivariate analysis. Correlation analysis showed that both adrenal width and the volume of the contralateral side had a significant association with the duration of steroid replacement. The reason that the contralateral adrenal volume did not have a statistical association on multivariate analysis might be due to the structure of the adrenal gland, which has two distinct parts -the outer adrenal cortex and the inner medulla. Atrophic change of the contralateral adrenal gland in SCS patients appears only in the adrenal cortex. Thus, the major axis and height is invariable, only the minor axis (width) would change and apparently reflect the atrophy of the contralateral adrenal gland in statistical analysis. In contrast, the shape of the adrenal glands differs among individuals, sometimes it pyramidal or semilunar. Therefore, volume, which was simply calculated as ellipsoid in the present study, might not reflect the precise atrophic change or shape of the contralateral adrenal gland. The present study had several limitations. The retrospective nature of the study might have affected the quality of the data, although all patients were studied uniformly before enrollment in this study. Second, the relatively small sample size limited the power of the study to identify fewer potential effects. Third, the endocrine physician decided the total duration of steroid replacement according to the degree of cortisol excess recovery after surgery; a more precise definition to stop post-surgical steroid replacement is necessary. Fourth, the amount of hydrocortisone as the post-operative steroid replacement was reduced during this study and might affect the total duration of steroid replacement.
In conclusion, contralateral adrenal width was the predictor of prolonged hypocortisolism requiring post-surgical steroid replacement in SCS patients. Pre-surgical assessment of imaging data might help clinicians determine the total duration of steroid therapy after adrenalectomy. The present findings might be helpful in appropriate counseling or providing a pre-surgical explanation for SCS patients undergoing adrenalectomy.
